Entering text into the input field will update the search result below

Neurocrine gains as Cantor calls valbenazine data “game changer” in Huntington's Disease

Dec. 08, 2021 12:46 PM ETNeurocrine Biosciences, Inc. (NBIX)By: Dulan Lokuwithana, SA News Editor

Huntington"s disease genetic test

Hailshadow/iStock via Getty Images

  • Neurocrine Biosciences (NBIX +2.4%) has gained for the third consecutive session after the company disclosed that its Phase 3 trial to assess Ingrezza (valbenazine) in chorea associated with Huntington's Disease met the primary endpoint.
  • After valbenazine

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.